"TCI offers full-service heart and vascular care throughout mid-Michigan, offering Patients the newest and most exciting treatment options available."

During the past decade, Thoracic and Cardiovascular Institute conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 3 clinical trials were completed, i.e. on average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Thoracic and Cardiovascular Institute" #1 sponsor was "Advanz Pharma" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "Alexion" with 1 trials sponsored, "Anesiva, Inc." with 1 trials sponsored and "Aziyo Biologics, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Thoracic and Cardiovascular Institute" #1 collaborator was "Astellas Pharma US, Inc." with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Thoracic and Cardiovascular Institute" are "Cardiovascular Disease" (3 trials), "Atrial Fibrillation" (2 trials), "Anti-coagulation Therapy" (1 trials), "Atrial Flutter" (1 trials) and "Cardiac Resynchronization Therapy" (1 trials). Many other conditions were trialed in "Thoracic and Cardiovascular Institute" in a lesser frequency.

Most popular intervention types in "Thoracic and Cardiovascular Institute" are "Drug" (6 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Vernakalant Injection 20 mg/mL" (2 trials), "bococizumab (PF-04950615)" (2 trials), "CGT003 (E2F Duplex Decoy)" (1 trials) and "Kronos LV-T, Lumax HF-T" (1 trials). Other intervention names were less common.

The vast majority of trials in "Thoracic and Cardiovascular Institute" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Thoracic and Cardiovascular Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Thoracic and Cardiovascular Institute, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Thoracic and Cardiovascular Institute, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".